FindMyKOL

Raymond Cho, MD

Enriched profile

Professor, Dermatology · University of California, San Francisco

ORCIDNone on fileNPI↗
✓ Itemized profile
Region🇺🇸 San Francisco, CA · West · United StatesSpecialtyDermatologyFocusAtopic Dermatitis / Eczema
Active KOLFindMyKOL type: EliteLatest publicationNone indexedOnline presenceNone verifiedPayments2021–2025NIH funding2000–2026Why? →

Raymond Cho is Professor, Dermatology at University of California, San Francisco. ClinicalTrials.gov lists 8 registered studies with this person as an investigator.

Data verified 27 Oct 2026

Overview

Updated 28 Oct 2026

Raymond Cho, M.D., PH.D., is Professor, Dermatology at University of California, San Francisco. It also documents an investigator role on 8 registered clinical trials, industry payments reported by 16 companies, 4 NIH-funded awards (2000–2026).

  • Top research focus: Atopic Dermatitis / Eczema
  • 8 registered trials on ClinicalTrials.gov
  • Open Payments reporting from 16 companies

Generated from the cited public record · current as of 28 Oct 2026. Every fact links its source below.

Indications focus

from trials led + research topics
Psoriasis / Psoriatic Arthritis5 trialsSchizophrenia2 trialsPsychotic Disorders2 trialsAtopic Dermatitis / Eczema2 trials

Research focus

OpenAlex concept fingerprint
Atopic Dermatitis / Eczema

Drugs & molecules

across trials, industry payments and publications
Dupixentgeneric · DupilumabClinical trials—Industry payments12Publications—Opzelurageneric · RuxolitinibClinical trials—Industry payments5Publications—Sotyktugeneric · DeucravacitinibClinical trials—Industry payments4Publications—Ilumyageneric · TildrakizumabClinical trials—Industry payments3Publications—Nemluviogeneric · NemolizumabClinical trials—Industry payments3Publications—Tremfyageneric · GuselkumabClinical trials—Industry payments3Publications—Vtamageneric · TapinarofClinical trials—Industry payments3Publications—Ayvakitgeneric · AvapritinibClinical trials—Industry payments2Publications—Adbrygeneric · TralokinumabClinical trials—Industry payments1Publications—Cibinqogeneric · AbrocitinibClinical trials—Industry payments1Publications—IsotretinoinClinical trials—Industry payments1Publications—Rinvoqgeneric · UpadacitinibClinical trials—Industry payments1Publications—

Works with

trial sponsors and companies reporting payments
Regeneron Pharmaceuticals, Inc.Clinical trials—Industry payments10E.R. Squibb & Sons, L.L.C.Clinical trials—Industry payments7Genzyme CorporationClinical trials—Industry payments7University of California, San FranciscoClinical trials6Industry payments—Galderma Laboratories, L.P.Clinical trials—Industry payments5Incyte CorporationClinical trials—Industry payments5Sun Pharmaceutical Industries Inc.Clinical trials—Industry payments4Abbvie Inc.Clinical trials—Industry payments3LEO Pharma Inc.Clinical trials—Industry payments3Baylor College of MedicineClinical trials2Industry payments—Dermavant Sciences, Inc.Clinical trials—Industry payments2Janssen Scientific Affairs, LLCClinical trials—Industry payments2Blueprint Medicines CorporationClinical trials—Industry payments1Janssen Biotech, Inc.Clinical trials—Industry payments1Organon LLCClinical trials—Industry payments1Pfizer Inc.Clinical trials—Industry payments1

Scholarship

indexed output and impact (OpenAlex)
View publications ↓
0h-index

Hirsch index, productivity × impact (OpenAlex).

Clinical & industry

trials, payments and federal funding
8clinical trials

Investigator role on registered studies.

View trials ↓
16companies · 2021–2025

Companies reporting payments to CMS. Facts, not judgments.

View payments ↓
4NIH grants · 2000–2026

Federally funded research awards.

View funding ↓

Contact

The practice address and phone this provider lists in the federal NPPES (CMS) registry.

Practice address

Telephone

Practice address and telephone from the federal NPPES registry.

Sign in to view contact details →

Clinical trials

Updated 28 Oct 2026

Listed as an investigator on 8 registered studies on ClinicalTrials.gov. The most recent:

All 8 trial records: search, sort and filter.Explore →

Industry payments

Updated 28 Oct 2026

16 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:

All 27 payment records: search, sort and filter.Explore →
View the CMS Open Payments record ↗

Medicare prescribing footprint (2024)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Dermatology

    31.2%
    Corticosteroid12.7%
    Triamcinolone Acetonide100%
    Part D≥55 patients
    Interleukin-4 Receptor alpha Antagonist8.1%
    Dupixent Pen66%Dupixent Syringe34%
    Part D<11 patients

    + 2 more classes in this area

  • Cancer & immunology

    17.8%
    Nucleoside Metabolic Inhibitor10.2%
    Fluorouracil100%
    Part D≥48 patients
    Folate Analog Metabolic Inhibitor3.4%
    Methotrexate100%
    Part D<11 patients

    + 2 more classes in this area

  • Cardiovascular

    16.6%
    Corticosteroid9.3%
    Fluocinonide100%
    Part D≥34 patients
    Arteriolar Vasodilator7.3%
    Minoxidil100%
    Part D<11 patients
All 9 therapeutic areas: search, sort and filter.Explore →
Where care is delivered (Part B)0% facility · 100% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

NIH funding

Updated 28 Oct 2026

4 NIH research awards on record, funded 2000–2026 per NIH RePORTER. The latest:

All 21 award records: search, sort and filter.Explore →

Publications

None on file yet. We only list publications we can confidently match to this person. Why? →

Background & recognition

Updated 28 Oct 2026

Credentials, appointments and honors, newest first, each linked to the public source it came from.

Education

degrees and training on record
  • M.D.

    Stanford University School of Medicine

    2005
    verifiedCorroborated by FindMyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →profiles.ucsf.edu ↗
  • Ph.D.

    Stanford University, Department of Genetics

    2003
    verifiedCorroborated by FindMyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →profiles.ucsf.edu ↗
  • Board certified in Dermatology

    American Board of Dermatology

    verifiedCorroborated by FindMyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →ucsfhealth.org ↗

Awards & honors

honors on the public record

Media & interviews

press, podcasts and appearances

Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.

Similar KOLs

Other experts from the same institution or the same specialty.